Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Somewhere deep in my mind, the guilt starts to build as I know this will only make things infinitely worse in the long run.

An expert discusses how the clinical presentations of atopic dermatitis (AD) vary across different patient populations and the challenges these variations pose in diagnosis.

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

Panelists discuss how atopic dermatitis, a chronic inflammatory skin condition characterized by intense itching and recurring ...

Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing ...

The only change she mentioned was, because it was frigid outside, she and her friends were going to the mall a lot where they ...

Ocular surface disease symptoms in individuals with comorbid atopic dermatitis are more common and severe, and self-rated vision is worse.

Experts say that getting infected with measles can pose serious health risks for people that they wouldn’t face if they were vaccinated ...